title: Antigenicity studies on catena-(S)-[mu-[N alpha-(3-aminopropionyl)histidinato(2-)-N1,N2,O:N tau]-zinc].
abstract: The antigenicity of Z-103 (catena-(S)-[mu[N alpha-(3-aminopropionyl) histidinato(2-)-N1,N2,O:N tau]-zinc], CAS 107667-60-7) was evaluated using the following assay procedures: 1. active systemic anaphylaxis (ASA) in guinea pigs. 2. passive cutaneous anaphylaxis (PCA) in guinea pigs with serum from guinea pigs sensitized with Z-103, 3. delayed type skin reaction (Maximization Test) in guinea pigs, 4. passive cutaneous anaphylaxis (PCA) in rats with serum from mice sensitized with Z-103 and 5. passive hemagglutination (PHA) with serum from mice sensitized with Z-103. In each test except for Maximization Test, the sera obtained 1 or 6 h (hereinafter designated as 1-h-sera or 6-h-sera) after a single oral administration of 500 mg/kg of Z-103 to the unused rats, guinea pigs or rabbits, were used as the challenge antigen. 1. ASA in guinea pigs: No anaphylaxis reaction was observed in any of the sensitized guinea pigs by elicitation with challenge antigen. 2. PCA in guinea pigs: PCA titer of sera from all the sensitized animals was less than 1 in elicitation with the challenge antigen. 3. Delayed type skin reaction test: No skin reaction was observed in sensitized guinea pigs after intradermal injection or dermal application of Z-103. 4. PCA in rats: PCA titer of sera from BALB/c and C3H/He mice sensitized with Z-103 was less than 5 in elicitation with the challenge antigen. 5. PHA reaction: When erythrocytes coated with challenge antigen were added to sensitized sera, the hemagglutination titer was less than 1.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Toxicology and Drug Metabolism, Zeria Pharmaceutical Co., Ltd., Saitama, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Shibata
authors.forename: K
authors.initials: K
authors.lastname: Matsuda
authors.forename: H
authors.initials: H
authors.lastname: Wada
authors.forename: F
authors.initials: F
authors.lastname: Aruga
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
mesh_terms: D000707:Anaphylaxis / Q000276:immunology; D000818:Animals; D000897:Anti-Ulcer Agents / Q000276:immunology*; D000941:Antigens / Q000276:immunology*; D002336:Carnosine / Q000031:analogs & derivatives*; D004151:Dipeptides / Q000276:immunology*; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006168:Guinea Pigs; D006386:Hemagglutination Tests; D006968:Hypersensitivity, Delayed / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009942:Organometallic Compounds / Q000276:immunology*; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D012756:Sheep / Q000276:immunology; D017967:Zinc Compounds
chemical_list: D000897:Anti-Ulcer Agents; D000941:Antigens; D004151:Dipeptides; D009942:Organometallic Compounds; D017967:Zinc Compounds; C061957:polaprezinc; D002336:Carnosine